logo
The New Era of Life Sciences: The Future is Now

The New Era of Life Sciences: The Future is Now

Newsweek16-05-2025
When we published our 2024 report, children suffering from Leber Congenital Amaurosis 4 (LCA4)—a severe inherited retinal dystrophy—had only hope that one day they might see the world. Today, thanks to an investigational gene therapy, we know that the 11 children who participated in the trials can, for the first time in their lives, discern a toy, recognize a human face and even spot a grain of sand. The biotech behind this achievement is MeiraGTx, which has now filed its therapy for approval under exceptional circumstances in the U.K., which would expedite the process.
Stories like that of MeiraGTx illustrate the transformative power of gene therapies on patients. More broadly, they highlight the potential for rare diseases R&D to emerge as the principal driver of therapeutic innovation. "Rare diseases have become a critical area for exploring new treatment modalities because, in many cases, there is no existing therapy, or even a model. For patients who have no options, innovative approaches are important," shares Marc Dunoyer, the CEO of Alexion, the rare diseases subsidiary of AstraZeneca. Ironically, the very severity and uncommonness of these illnesses can also be a blessing, as it allows for bolder approaches by both researchers and regulators. Moreover, rare disease drugs have historically had higher approval success rates compared to other drugs. The Tufts Center for the Study of Drug Development found that orphan-designated drugs had a Phase-1-to-approval success rate of 17 percent, compared to 7.9 percent for non-orphan drugs. Benefiting from faster approval pathways and enhanced regulatory incentives, entrepreneurs in the field face better odds of innovating successfully.
And when they do, the implications of their therapies go far beyond their original target. "Many of the advances seen today, such as gene editing and RNA-based therapies, originated in rare disease research before moving into larger indications," says Dunoyer. Arcturus Therapeutics, for instance, is addressing cystic fibrosis via a new delivery mechanism. "Our cystic fibrosis program is a prime example, where the ability to inhale mRNA safely could have a huge impact on the pharmaceutical industry. The rare disease field offers a shorter regulatory pathway to approval and a higher likelihood of success. This makes it an attractive space for evaluating next-generation technologies like mRNA therapeutics," shares Arcturus' CEO, Joseph Payne, as the company is expecting results from their Phase 2 trials in 2025.
Matt Sause, CEO, Roche Diagnostics. Credit: Courtesy of Roche Diagnostics.
Matt Sause, CEO, Roche Diagnostics. Credit: Courtesy of Roche Diagnostics.
We can perform comprehensive genomic profiling to uncover the molecular basis of a tumor. This allows doctors to provide tailored treatments. Over time, this will enable us to move to a future where we understand the molecular drivers for cancer and can deliver truly personalized healthcare.
Jacob Thaysen, CEO, Illumina. Credit: Courtesy of Illumina.
Jacob Thaysen, CEO, Illumina. Credit: Courtesy of Illumina.
Whether it is providing clarity for families dealing with rare genetic disorders or enabling rapid and precise cancer diagnoses, our goal is to ensure patients receive the answers they need when they need them.
This report has been paid for by a third party. The views and opinions expressed are not those of Newsweek and are not an endorsement of the products, services or persons mentioned.
Click here to download the full report
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation
AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation

Yahoo

time12 hours ago

  • Yahoo

AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation

AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of its most notable experimental drugs, AZD5004 and AZD6234, show potential in the weight management space. In total, the company is advancing nearly 200 research programs across its development pipeline. AstraZeneca PLC (NASDAQ:AZN) recently announced plans to invest $50 billion in the US by 2030. This initiative is expected to generate tens of thousands of direct and indirect jobs nationwide. A key part of the investment includes the development of a new multi-billion-dollar manufacturing site in the US, which will focus on producing drug substances for its weight management and metabolic treatments—such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. This commitment comes on top of the $3.5 billion investment the company revealed in November 2024. AstraZeneca PLC (NASDAQ:AZN) is a solid dividend payer, as it has paid uninterrupted dividends to shareholders for the past 32 years. The company offers an interim dividend of $1.03 per share and has a dividend yield of 2.13%, as of July 25. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.

AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation
AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation

Yahoo

time13 hours ago

  • Yahoo

AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation

AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of its most notable experimental drugs, AZD5004 and AZD6234, show potential in the weight management space. In total, the company is advancing nearly 200 research programs across its development pipeline. AstraZeneca PLC (NASDAQ:AZN) recently announced plans to invest $50 billion in the US by 2030. This initiative is expected to generate tens of thousands of direct and indirect jobs nationwide. A key part of the investment includes the development of a new multi-billion-dollar manufacturing site in the US, which will focus on producing drug substances for its weight management and metabolic treatments—such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. This commitment comes on top of the $3.5 billion investment the company revealed in November 2024. AstraZeneca PLC (NASDAQ:AZN) is a solid dividend payer, as it has paid uninterrupted dividends to shareholders for the past 32 years. The company offers an interim dividend of $1.03 per share and has a dividend yield of 2.13%, as of July 25. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pharma's turbo spending spree on US manufacturing
Pharma's turbo spending spree on US manufacturing

Yahoo

timea day ago

  • Yahoo

Pharma's turbo spending spree on US manufacturing

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Investments in U.S. drug manufacturing are skyrocketing. Pharma giants everywhere have announced massive, multi-year deals to build and expand facilities across the country as several market factors make the U.S. a favorable destination for producing branded drugs. The looming threat of U.S. tariffs remains a motivator for companies from around the globe. Earlier this month, President Donald Trump said tariffs as high as 200% on pharma products would be introduced 'very soon.' Other industry shifts, including the growing GLP-1 market and the demand for skilled workers in pharma's tech-heavy manufacturing environment, are also tipping the scales toward the U.S. Amid the investment boom, tens of billions of dollars are pouring into manufacturing hubs like Raleigh, North Carolina, and generating thousands of job openings for engineers, R&D personnel, operations professionals and more. Here's a look at the latest companies to hop on the U.S. manufacturing bandwagon. AstraZeneca makes its largest-ever single facility investment AstraZeneca joined the $50 billion club this month when it announced a sprawling manufacturing and R&D investment in the U.S. The size of the investment matches the other leading pledges from pharma companies this year — including Roche, Johnson & Johnson and Eli Lilly — to each pump $50 billion or more into U.S. facilities. CEO Pascal Soroit acknowledged that tariffs played a part in the U.K.-based company's decision to pump up its U.S. operations in a recent interview with Fortune, but also noted that Europe is 'losing ground' as a drug production destination by focusing on 'social benefits and managing costs.' AstraZeneca's plan includes $4 billion for a drug substance facility in Virginia — its largest single-facility manufacturing investment in the world. But the $50 billion in funds will stretch across the country and include an R&D expansion in Maryland, a continuous manufacturing expansion in Indiana, a next-generation cell therapy facility in Texas, a 'state of the art' R&D center in Massachusetts' biotech hub at Kendall Square and more. The American market for drugs also plays a starring role in the company's broader ambitions. All told, AstraZeneca aims to boost its total revenue from the $54 billion-mark it hit in 2024 to over $80 billion by 2030 — half of which it expects to be generated in the U.S., the company said. Biogen pours more into North Carolina Biogen is broadening its manufacturing footprint in North Carolina. The company said it will invest $2 billion into two campuses in the state's Research Triangle Park, Biogen's current hub for manufacturing. The fresh funds will expand Biogen's capacity for multiple modalities, including antisense oligonucleotides, while modernizing its operations with automation and AI. Biogen is still working to move past its Aduhelm debacle. The Eisai-partnered Alzheimer's drug notched a historic approval in 2021 but was later pulled from the market amid cost and efficacy controversies. Its other Alzheimer's treatment Leqembi has had a stronger showing on the market and has steadily risen in sales since last year. But Biogen has also been in cost-cutting mode since 2023 and expects revenue to decline this year. Going forward, the company is leaning on its pipeline, including treatments for Dravet syndrome, a rare form of epilepsy, to set the stage for future growth. Its latest manufacturing investment adds to the $10 billion it has funneled into North Carolina since setting up shop at Research Triangle Park in 1995. Thermo Fisher snags Sanofi facility to boost fill-finish chops Thermo Fisher Scientific is expanding its production prowess with the help of a growing Sanofi partnership. The companies said this month that Thermo Fisher is snapping up a sterile, fill-finish manufacturing site from the French pharma for an undisclosed sum. The move comes amid higher-than-expected profit last quarter for Thermo Fisher, one of the pharma industry's key suppliers of clinical research services and equipment. The new digs will help Thermo Fisher 'strengthen' its U.S. manufacturing capabilities for the broader pharma industry, the company stated. The latest move is also a part of the four-year, $2 billion commitment to U.S. manufacturing Thermo Fisher announced in April. Recommended Reading Tracking a moving target: Drugmakers brace for a looming tariff impact

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store